{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vaccine+Candidate+%235&page=2",
    "query": {
      "intervention": "Vaccine Candidate #5",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 55,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vaccine+Candidate+%235&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vaccine+Candidate+%235&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-02T10:49:34.590Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06265012",
      "title": "Study to Evaluate the Recombinant VSV (rVSV)-Marburg Virus Vaccine Candidate (PHV01) in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Marburg Virus Disease"
      ],
      "interventions": [
        {
          "name": "PHV01",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Public Health Vaccines LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 36,
      "start_date": "2024-02-05",
      "completion_date": "2024-09-23",
      "has_results": false,
      "last_update_posted_date": "2025-09-05",
      "last_synced_at": "2026-10-02T10:49:34.590Z",
      "location_count": 1,
      "location_summary": "Hollywood, Florida",
      "locations": [
        {
          "city": "Hollywood",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06265012"
    },
    {
      "nct_id": "NCT06237296",
      "title": "Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infection",
        "Healthy Volunteers",
        "Metapneumovirus Infection"
      ],
      "interventions": [
        {
          "name": "RSV/hMPV mRNA LNP 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV/hMPV mRNA LNP 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV mRNA LNP 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "hMPV mRNA LNP 1",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 558,
      "start_date": "2024-01-23",
      "completion_date": "2025-02-11",
      "has_results": false,
      "last_update_posted_date": "2025-09-11",
      "last_synced_at": "2026-10-02T10:49:34.590Z",
      "location_count": 9,
      "location_summary": "Gardena, California • Hallandale, Florida • Meridian, Idaho + 6 more",
      "locations": [
        {
          "city": "Gardena",
          "state": "California"
        },
        {
          "city": "Hallandale",
          "state": "Florida"
        },
        {
          "city": "Meridian",
          "state": "Idaho"
        },
        {
          "city": "Sioux City",
          "state": "Iowa"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06237296"
    },
    {
      "nct_id": "NCT05854381",
      "title": "To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV I Infection"
      ],
      "interventions": [
        {
          "name": "VIR-1388",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 93,
      "start_date": "2023-09-19",
      "completion_date": "2025-11-19",
      "has_results": false,
      "last_update_posted_date": "2026-03-03",
      "last_synced_at": "2026-10-02T10:49:34.590Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Decatur, Georgia • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05854381"
    },
    {
      "nct_id": "NCT06719219",
      "title": "A First in Human Trial to Assess the Safety and Immunogenicity of LTB-SA7 Vaccine Against Staphylococcus Aureus.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Staphylococcus (S.) Aureus Infection"
      ],
      "interventions": [
        {
          "name": "LTB-SA7",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "LimmaTech Biologics AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 129,
      "start_date": "2025-01-07",
      "completion_date": "2026-03-04",
      "has_results": false,
      "last_update_posted_date": "2026-08-03",
      "last_synced_at": "2026-10-02T10:49:34.590Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06719219"
    },
    {
      "nct_id": "NCT06337643",
      "title": "A Study to Evaluate Tolerability, Safety and Immunogenicity of MVX01 Pneumococcal Vaccine",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pneumococcal Vaccine"
      ],
      "interventions": [
        {
          "name": "MVX01",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MVX01 Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Matrivax Research and Development Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 75,
      "start_date": "2023-03-07",
      "completion_date": "2024-04-16",
      "has_results": false,
      "last_update_posted_date": "2024-03-29",
      "last_synced_at": "2026-10-02T10:49:34.590Z",
      "location_count": 2,
      "location_summary": "Savannah, Georgia • Knoxville, Tennessee",
      "locations": [
        {
          "city": "Savannah",
          "state": "Georgia"
        },
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06337643"
    },
    {
      "nct_id": "NCT02193087",
      "title": "Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dengue Fever"
      ],
      "interventions": [
        {
          "name": "TDV Liquid Formulation 1",
          "type": "DRUG"
        },
        {
          "name": "TDV Liquid Formulation 2",
          "type": "DRUG"
        },
        {
          "name": "TDV IDT Lyophilized",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 1002,
      "start_date": "2014-08-06",
      "completion_date": "2015-05-19",
      "has_results": true,
      "last_update_posted_date": "2019-07-18",
      "last_synced_at": "2026-10-02T10:49:34.590Z",
      "location_count": 7,
      "location_summary": "Phoenix, Arizona • Anaheim, California • Stockbridge, Georgia + 4 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Stockbridge",
          "state": "Georgia"
        },
        {
          "city": "Meridian",
          "state": "Idaho"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02193087"
    },
    {
      "nct_id": "NCT00375726",
      "title": "Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3/4delta30[ME]) in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dengue"
      ],
      "interventions": [
        {
          "name": "rDEN3/4delta30(ME)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 58,
      "start_date": "2006-10",
      "completion_date": "2008-09",
      "has_results": false,
      "last_update_posted_date": "2010-12-14",
      "last_synced_at": "2026-10-02T10:49:34.590Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00375726"
    },
    {
      "nct_id": "NCT01006798",
      "title": "Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bird Flu",
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Ad4-H5-Vtn",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sanofi Pasteur Influenza Virus Vaccine, H5N1",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Emergent BioSolutions",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 166,
      "start_date": "2009-10",
      "completion_date": "2011-09",
      "has_results": false,
      "last_update_posted_date": "2024-03-18",
      "last_synced_at": "2026-10-02T10:49:34.590Z",
      "location_count": 4,
      "location_summary": "Lexington, Kentucky • Kansas City, Missouri • Rochester, New York + 1 more",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Mt. Pleasant",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01006798"
    },
    {
      "nct_id": "NCT00094705",
      "title": "Safety of and Immune Response to a Dengue Virus Vaccine (rDEN2/4delta30[ME]) in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dengue Fever"
      ],
      "interventions": [
        {
          "name": "rDEN2/4delta30(ME) Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 28,
      "start_date": "2005-01",
      "completion_date": "2006-04",
      "has_results": false,
      "last_update_posted_date": "2008-01-21",
      "last_synced_at": "2026-10-02T10:49:34.590Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00094705"
    },
    {
      "nct_id": "NCT06118151",
      "title": "Safety and Immunogenicity of a Monovalent mRNA Vaccine Encoding Influenza Hemagglutinin in Adult Participants 18 Years of Age and Older",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza",
        "Influenza Immunization"
      ],
      "interventions": [
        {
          "name": "Influenza Hemagglutinin mRNA vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quadrivalent Recombinant Influenza Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 388,
      "start_date": "2022-04-11",
      "completion_date": "2023-02-17",
      "has_results": false,
      "last_update_posted_date": "2023-11-07",
      "last_synced_at": "2026-10-02T10:49:34.590Z",
      "location_count": 20,
      "location_summary": "Rolling Hills Estates, California • San Diego, California • Coral Gables, Florida + 14 more",
      "locations": [
        {
          "city": "Rolling Hills Estates",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Savannah",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06118151"
    }
  ]
}